4.1 Article

Steady-state nevirapine plasma concentrations are influenced by pregnancy

Related references

Note: Only part of the references are listed.
Article Infectious Diseases

Safety of nevirapine in pregnancy

U. Natarajan et al.

HIV MEDICINE (2007)

Article Pharmacology & Pharmacy

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy

Nils von Hentig et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)

Article Immunology

Reduced lopinavir exposure during pregnancy

Alice M. Stek et al.

Article Pharmacology & Pharmacy

Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women

P. Villani et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)

Review Pharmacology & Pharmacy

Controversies in the use of nevirapine for prevention of mother-to-child transmission HIV

JA McIntyre

EXPERT OPINION ON PHARMACOTHERAPY (2006)

Article Immunology

Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy

F Van Leth et al.

AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)

Article Immunology

Nelfinavir and nevirapine side effects during pregnancy

S Timmermans et al.

Review Pharmacology & Pharmacy

Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach

GD Anderson

CLINICAL PHARMACOKINETICS (2005)

Article Immunology

Nelfinavir plasma concentrations are low during pregnancy

JFJB Nellen et al.

CLINICAL INFECTIOUS DISEASES (2004)

Article Medical Laboratory Technology

Race is not associated with nevirapine pharmacokinetics

MMR de Maat et al.

THERAPEUTIC DRUG MONITORING (2004)

Review Pharmacology & Pharmacy

Pharmacokinetics of antiretrovirals in pregnant women

M Mirochnick et al.

CLINICAL PHARMACOKINETICS (2004)

Review Pharmacology & Pharmacy

Drug interactions between antiretroviral drugs and comedicated agents

MMR de Maat et al.

CLINICAL PHARMACOKINETICS (2003)

Review Pharmacology & Pharmacy

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

TEMS de Vries-Sluijs et al.

CLINICAL PHARMACOKINETICS (2003)

Review Pharmacology & Pharmacy

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

PF Smith et al.

CLINICAL PHARMACOKINETICS (2001)